Notícias e Atividades da InnoCare

InnoCare é uma empresa listada sob o símbolo 09969 (HK).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da InnoCare

• Jasmine Cui, President and Chief Executive Officer
• Ronggang Xie, Director
• Jisong Cui, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da InnoCare.

InnoCare possui 1.920 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• David Ricks - President, Chief Executive Officer and Chairman of the Board da Eli Lilly
• Richard Saynor - Chief Executive Officer da Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de InnoCare

• Together towards the Future | INNOCARE
• Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH | INNOCARE
• InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China | INNOCARE
• InnoCare 2024 Q3 Results Earnings Call | INNOCARE
• InnoCare to Hold 2024 R&D Day on November 14, 2024 | INNOCARE
• InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients | INNOCARE
• InnoCare Announces End-of-Phase 2 Meeting with FDA and Agreement to Initiate a Phase III clinical trial of orelabrutinib for the treatment of PPMS | INNOCARE
• Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024 | INNOCARE
• InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China | INNOCARE
• InnoCare Business Update Conference Call | INNOCARE
• View more press releases Close

Redes sociais sobre InnoCare

• InnoCare na Wikipedia, Google News e Yahoo Finance
• InnoCare na LinkedIn, X (Twitter) e YouTube